TWI916370B - 用於在癌症治療中對不可標定之kras進行降解標定之新穎小分子 - Google Patents

用於在癌症治療中對不可標定之kras進行降解標定之新穎小分子

Info

Publication number
TWI916370B
TWI916370B TW110120388A TW110120388A TWI916370B TW I916370 B TWI916370 B TW I916370B TW 110120388 A TW110120388 A TW 110120388A TW 110120388 A TW110120388 A TW 110120388A TW I916370 B TWI916370 B TW I916370B
Authority
TW
Taiwan
Prior art keywords
compound
kras
cancer
mutant
compounds
Prior art date
Application number
TW110120388A
Other languages
English (en)
Chinese (zh)
Other versions
TW202210465A (zh
Inventor
巴斯卡倫 皮萊
莫魯根吉利札 迪奈希
Original Assignee
美商皮萊環球有限責任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商皮萊環球有限責任公司 filed Critical 美商皮萊環球有限責任公司
Publication of TW202210465A publication Critical patent/TW202210465A/zh
Application granted granted Critical
Publication of TWI916370B publication Critical patent/TWI916370B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
TW110120388A 2020-06-04 2021-06-04 用於在癌症治療中對不可標定之kras進行降解標定之新穎小分子 TWI916370B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN202041023434 2020-06-04
IN202041023434 2020-06-04
PCT/IB2021/054591 WO2021245499A1 (en) 2020-06-04 2021-05-26 Novel small molecules for targeted degradation of untargetable kras in cancer therapy
WOPCT/IB2021/054591 2021-05-26

Publications (2)

Publication Number Publication Date
TW202210465A TW202210465A (zh) 2022-03-16
TWI916370B true TWI916370B (zh) 2026-03-01

Family

ID=78830675

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110120388A TWI916370B (zh) 2020-06-04 2021-06-04 用於在癌症治療中對不可標定之kras進行降解標定之新穎小分子

Country Status (12)

Country Link
US (1) US20230202981A1 (cg-RX-API-DMAC7.html)
EP (1) EP4161511B1 (cg-RX-API-DMAC7.html)
JP (1) JP7789016B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230019937A (cg-RX-API-DMAC7.html)
CN (2) CN115768427B (cg-RX-API-DMAC7.html)
AU (1) AU2021284517A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022024300A2 (cg-RX-API-DMAC7.html)
CA (1) CA3180686A1 (cg-RX-API-DMAC7.html)
IL (1) IL298672A (cg-RX-API-DMAC7.html)
MX (1) MX2022015253A (cg-RX-API-DMAC7.html)
TW (1) TWI916370B (cg-RX-API-DMAC7.html)
WO (1) WO2021245499A1 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020020307A2 (pt) 2018-04-04 2021-01-12 Arvinas Operations, Inc. Moduladores de proteólise e métodos de uso associados
WO2019217307A1 (en) 2018-05-07 2019-11-14 Mirati Therapeutics, Inc. Kras g12c inhibitors
CA3112043A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
US12208099B2 (en) 2018-09-10 2025-01-28 Mirati Therapeutics, Inc. Combination therapies
AU2019338207B2 (en) 2018-09-10 2025-01-02 Mirati Therapeutics, Inc. Combination therapies
SMT202500028T1 (it) 2018-09-10 2025-03-12 Mirati Therapeutics Inc Terapie combinate
US12377101B2 (en) 2018-12-05 2025-08-05 Mirati Therapeutics, Inc. Combination therapies
WO2020146613A1 (en) 2019-01-10 2020-07-16 Mirati Therapeutics, Inc. Kras g12c inhibitors
CN114615981B (zh) 2019-08-29 2024-04-12 米拉蒂治疗股份有限公司 Kras g12d抑制剂
CN114761012B (zh) 2019-09-24 2025-03-21 米拉蒂治疗股份有限公司 组合疗法
PH12022551513A1 (en) 2019-12-20 2023-04-24 Mirati Therapeutics Inc Sos1 inhibitors
US12655160B2 (en) 2020-08-04 2026-06-16 Mirati Therapeutics, Inc. KRAS G12D inhibitors
EP4210833A4 (en) 2020-09-11 2024-09-11 Mirati Therapeutics, Inc. CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR
EP4216951B1 (en) 2020-09-22 2026-04-01 Mirati Therapeutics, Inc. Kras g12d inhibitors
EP4262807A4 (en) 2020-12-15 2025-04-23 Mirati Therapeutics, Inc. Azachinazoline pan-KRAS inhibitors
WO2022133038A1 (en) 2020-12-16 2022-06-23 Mirati Therapeutics, Inc. Tetrahydropyridopyrimidine pan-kras inhibitors
PE20260006A1 (es) 2023-01-26 2026-01-06 Arvinas Operations Inc Protacs degradadores de kras basados en cereblon y usos relacionados con los mismos
WO2025083564A1 (en) * 2023-10-18 2025-04-24 Pillai Universal Llc Novel small molecule degrader as a potential anticancer
WO2025083561A1 (en) * 2023-10-18 2025-04-24 Pillai Universal Llc Novel lead small molecule inhibitors on undruggable target towards anticancer activity
WO2025083570A1 (en) * 2023-10-18 2025-04-24 Pillai Universal Llc Novel small-molecule agents in overcoming tumor regression in cancers
WO2025083563A1 (en) * 2023-10-18 2025-04-24 Pillai Universal Llc Effective therapeutic small-molecule inhibitors for metastatic cancer
WO2025083568A1 (en) * 2023-10-18 2025-04-24 Pillai Universal Llc Novel small-molecule protein kinase inhibitors for implications in cancer treatment

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001090101A1 (en) 2000-05-22 2001-11-29 Aventis Pharmaceuticals Inc. Arylmethylamine derivatives for use as tryptase inhibitors
WO2007075896A2 (en) 2005-12-22 2007-07-05 Kemia, Inc. Heterocyclic cytokine inhibitors
WO2011130628A1 (en) 2010-04-16 2011-10-20 Curis, Inc. Treatment of cancers having k-ras mutations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0012362D0 (en) * 2000-05-22 2000-07-12 Aventis Pharma Ltd Chemical compounds
IL161662A0 (en) * 2001-11-01 2004-09-27 Janssen Pharmaceutica Nv Heteroaryl amines as glycogen synthase kinase 3 beta inhibitors (gsk3 inhibitors)
US20190284149A1 (en) * 2014-09-12 2019-09-19 Ariagen, Inc. Aryl hydrocarbon receptor modulator
CN106317055A (zh) * 2015-07-02 2017-01-11 中国科学院上海药物研究所 一类具有激酶抑制活性的化合物、制备方法和用途
EP3573971A1 (en) * 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
CN110885332B (zh) * 2019-12-06 2022-03-18 中国人民解放军第二军医大学 一种PDEδ蛋白降解靶向嵌合体及其制备方法和应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001090101A1 (en) 2000-05-22 2001-11-29 Aventis Pharmaceuticals Inc. Arylmethylamine derivatives for use as tryptase inhibitors
WO2007075896A2 (en) 2005-12-22 2007-07-05 Kemia, Inc. Heterocyclic cytokine inhibitors
WO2011130628A1 (en) 2010-04-16 2011-10-20 Curis, Inc. Treatment of cancers having k-ras mutations

Also Published As

Publication number Publication date
KR20230019937A (ko) 2023-02-09
EP4161511B1 (en) 2026-04-29
MX2022015253A (es) 2023-03-14
IL298672A (en) 2023-01-01
BR112022024300A2 (pt) 2023-01-24
CA3180686A1 (en) 2021-12-09
CN115768427B (zh) 2025-03-28
CN115768427A (zh) 2023-03-07
US20230202981A1 (en) 2023-06-29
WO2021245499A1 (en) 2021-12-09
JP7789016B2 (ja) 2025-12-19
EP4161511A1 (en) 2023-04-12
JP2023529354A (ja) 2023-07-10
CN120208921A (zh) 2025-06-27
TW202210465A (zh) 2022-03-16
EP4161511A4 (en) 2024-07-17
AU2021284517A1 (en) 2023-01-05

Similar Documents

Publication Publication Date Title
EP4161511B1 (en) Novel small molecules for targeted degradation of untargetable kras in cancer therapy
US20240082218A1 (en) Pharmaceutical combinations comprising a kras g12c inhibitor and uses of a kras g12c inhibitor for the treatment of cancers
JP6193268B2 (ja) Cdk8/cdk19選択的阻害剤、ならびに癌のための抗転移および化学防御の方法におけるそれらの使用
He et al. Targeting cullin neddylation for cancer and fibrotic diseases
AU2013235425B2 (en) Inhibition of MCL-1 and/or BFL-1/A1
CN112585136B (zh) 作为smarca2/brm atp酶抑制剂的脲化合物和组合物
Devambatla et al. Design, synthesis, and preclinical evaluation of 4-substituted-5-methyl-furo [2, 3-d] pyrimidines as microtubule targeting agents that are effective against multidrug resistant cancer cells
Li et al. Discovery, synthesis, and evaluation of novel dual inhibitors of a vascular endothelial growth factor receptor and poly (ADP-ribose) polymerase for BRCA wild-type breast cancer therapy
CN107666906A (zh) 用于治疗癌症的方法
EP3125901B1 (en) Derivatives of cephalosporin for treating cancer
JP2025542187A (ja) 進行性固形腫瘍の治療方法
CN103917514A (zh) 治疗包括骨髓增生性肿瘤和慢性骨髓性白血病在内的与转导素β样蛋白1(TBL1)活性相关的疾病和病症的方法
JP2013504550A (ja) 癌細胞アポトーシス
WO2014002922A1 (ja) 抗癌剤の併用による癌治療方法
JP6373252B2 (ja) オーロラキナーゼ阻害薬を使用する癌の治療方法
RU2839932C1 (ru) Новые малые молекулы для целенаправленного расщепления не поддающегося целенаправленному воздействию kras в терапии рака
Sampat et al. Inhibitors of the p21 activated kinases
Greco Synthesis and biological evaluation of pyrazolo [3, 4-d] pyrimidine derivatives active as SGK1, Fyn and Src kinases inhibitors
WO2026006342A1 (en) Direct-binding dual inhibitors of hypoxia-inducible factor 1 (hif-1) and hif-2
WO2025083565A1 (en) Phenotype and genotype target-based small molecule inhibitors in cancers
TW201605449A (zh) 馬賽替尼治療結腸直腸癌的用途
JP2015163592A (ja) 抗癌剤の併用による癌治療方法
HK1233924A1 (en) Derivatives of cephalosporin for treating cancer
HK1233924B (en) Derivatives of cephalosporin for treating cancer
HK1244482A1 (zh) 用於治疗神经母细胞瘤的组合